Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery

Molecular Pharmaceutics

Volumn 11, Issue 4, 2014, Pages 1335-1344

  Larregieu, Caroline A ^a   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biopharmaceutics classification system (BCS); biopharmaceutics drug disposition classification system (BDDCS); Caco 2; drug metabolism; intestinal absorption; PAMPA; permeability rate

Indexed keywords

METOPROLOL;

ARTICLE; BIOPHARMACEUTICS CLASSIFICATION SYSTEM; BIOPHARMACEUTICS DRUG DISTRIBUTION CLASSIFICATION SYSTEM; CELL STRAIN CACO 2; COMPARATIVE STUDY; DRUG ABSORPTION; DRUG DISPOSITION; DRUG METABOLISM; DRUG PENETRATION; HUMAN; INTESTINE ABSORPTION; PHARMACEUTICS; PREDICTION; PRIORITY JOURNAL; CACO 2 CELL LINE; DRUG DEVELOPMENT; DRUG INDUSTRY; PERMEABILITY;

CACO-2 CELLS; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; INTESTINAL ABSORPTION; PERMEABILITY;

EID: 84898006099     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp4007858     Document Type: Article

References (46)

1. Li, A. P. Screening for Human ADME/Tox Drug Properties in Drug Discovery Drug Discov. Today 2001, 6, 357-366
2. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of In Vitro Drug Product Dissolution and In Vivo Bioavailability Pharm. Res. 1995, 12, 413-420
3. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. FDA Guidance for Industry; Food and Drug Administration: Rockville, MD, 2000.
4. Lennernas, H. Intestinal Permeability and its Relevance for Absorption and Elimination Xenobiotica 2007, 37, 1015-1051
5. Ungell, A. L. Caco-2 Replace or Refine? Drug Discov. Today Tech. 2004, 1, 423-430
6. Varma, M. V.; Khandavilli, S.; Ashokraj, Y.; Jain, A.; Dhanikula, A.; Sood, A.; Thomas, N. S.; Pillai, O.; Sharma, P.; Gandhi, R.; Agrawal, S.; Nair, V.; Panchagnula, R. Biopharmaceutic Classification System: a Scientific Framework for Pharmacokinetic Optimization in Drug Research Curr. Drug Metab. 2004, 5, 375-388
7. Wu, C. Y.; Benet, L. Z. Predicting Drug Disposition via Application of BCS: Transport/Absorption/Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System Pharm. Res. 2005, 22, 11-23
8. Shugarts, S.; Benet, L. Z. The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs Pharm. Res. 2009, 26, 2039-2054
9. Broccatelli, F.; Larregieu, C. A.; Cruciani, G.; Oprea, T. I.; Benet, L. Z. Improving the Prediction of the Brain Disposition for Orally Administered Drugs Using BDDCS Adv. Drug Delivery Rev. 2012, 64, 95-109
10. Benet, L. Z.; Amidon, G. L.; Barends, D. M.; Lennernas, H.; Polli, J. E.; Shah, V. P.; Stavchansky, S. A.; Yu, L. X. The Use of BDDCS in Classifying the Permeability of Marketed Drugs Pharm. Res. 2008, 25, 483-488
11. Takagi, T.; Ramachandran, C.; Bermejo, M.; Yamashita, S.; Yu, L. X.; Amidon, G. L. A Provisional Biopharmaceutical Classification of the Top 200 Oral Drug Products in the United States, Great Britain, Spain, and Japan Mol. Pharmaceutics 2006, 3, 631-643
12. Dahan, A.; Miller, J. M.; Amidon, G. L. Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World's Top Oral Drugs AAPS J 2009, 11, 740-6
13. Chen, M. L.; Yu, L. The Use of Drug Metabolism for Prediction of Intestinal Permeability Mol. Pharmaceutics 2009, 6, 74-81
14. Varma, M. V.; Gardner, I.; Steyn, S. J.; Nkansah, P.; Rotter, C. J.; Whitney-Pickett, C.; Zhang, H.; Di, L.; Cram, M.; Fenner, K. S.; El-Kattan, A. F. pH-Dependent Solubility and Permeability Criteria for Provisional Biopharmaceutics Classification (BCS and BDDCS) in Early Drug Discovery Mol. Pharmaceutics 2012, 9, 1199-1212
15. Larregieu, C. A.; Benet, L. Z. The Confounding FDA Redefinition of Intestinal Permeability in Terms of Extent of Absorption. AAPS J. 2009, 11, Abstract W1840.
16. Benet, L. Z.; Larregieu, C. A. The FDA Should Eliminate the Ambiguities in the Current BCS Biowaiver Guidance and Make Public the Drugs for Which BCS Biowaivers Have Been Granted Clin. Pharmacol. Ther. 2010, 88, 405-407
17. Chen, M. L.; Amidon, G. L.; Benet, L. Z.; Lennernas, H.; Yu, L. X. The BCS, BDDCS, and Regulatory Guidances Pharm. Res. 2012, 28, 1774-1778
18. Larregieu, C. A.; Benet, L. Z. Drug Discovery and Regulatory Considerations for Improving In Silico and In Vitro Predictions that Use Caco-2 as a Surrogate for Human Intestinal Permeability Measurements AAPS J. 2013, 15, 483-497
19. Kansy, M.; Senner, F.; Gubernator, K. Physicochemical High Throughput Screening: Parallel Artificial Membrane Permeation Assay in the Description of Passive Absorption Processes J. Med. Chem. 1998, 41, 1007-1010
20. Chen, X.; Murawski, A.; Patel, K.; Crespi, C. L.; Balimane, P. V. A Novel Design of Artificial Membrane for Improving the PAMPA Model Pharm. Res. 2008, 25, 1511-1520
21. Sugano, K.; Takata, N.; Machida, M.; Saitoh, K.; Terada, K. Prediction of Passive Intestinal Absorption Using Bio-Mimetic Artificial Membrane Permeation Assay and the Paracellular Pathway Model Int. J. Pharm. 2002, 241, 241-251
22. Zhu, C.; Jiang, L.; Chen, T. M.; Hwang, K. K. A Comparative Study of Artificial Membrane Permeability Assay for High Throughput Profiling of Drug Absorption Potential Eur. J. Med. Chem. 2002, 37, 399-407
23. Benet, L. Z.; Øie, S.; Schwarz., J. B. Design and Optimization of Dosage Regimens: Pharmacokinetic Data. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9 th ed.; Hardman, J. G.;; Limbird, L. E.;; Molinoff, P. B.;; Ruddon, R. W.;; Gilman., A. G.; McGraw Hill: New York, 1996; pp 1707-1792.
24. Thummel, K. E.; Shen, D. D. Design and Optimization of Dosage Regimens: Pharmacokinetic Data. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10 th ed.; Hardman, J. G.; Limbird, L. E., Eds.; McGraw Hill: New York, 2001; pp 1924-2023.
25. Lacy, C. F.; Armstrong, L. L.; Goldman, M. P.; Lance, L. L. Drug Information Handbook: A Comprehensive Resource for All Clinicians and Healthcare Professionals, 19 th ed.; Lexi-Comp, Inc.: Hudson, OH, 2010; p 16-1655.
26. DRUGDEX® System [Internet database]. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc.; http://www.rubali.com/new/index.php?option=com- content&view=article&id=6&Itemid=121 (accessed Feb 2014); updated periodically.
27. Alsenz, J.; Haenel, E. Development of a 7-day, 96-Well Caco-2 Permeability Assay with High-Throughput Direct UV Compound Analysis Pharm. Res. 2003, 20, 1961-1969
28. Irvine, J. D.; Takahashi, L.; Lockhart, K.; Cheong, J.; Tolan, J. W.; Selick, H. E.; Grove, J. R. MDCK (Madin-Darby Canine Kidney) Cells: A Tool for Membrane Permeability Screening J. Pharm. Sci. 1999, 88, 28-33
29. Li, C.; Liu, T.; Cui, X.; Uss, A. S.; Cheng, K. C. Development of In Vitro Pharmacokinetic Screens Using Caco-2, Human Hepatocyte, and Caco-2/Human Hepatocyte Hybrid Systems for the Prediction of Oral Bioavailability in Humans J. Biomol. Screening 2007, 12, 1084-1091
30. Yazdanian, M.; Glynn, S. L.; Wright, J. L.; Hawi, A. Correlating Partitioning and Caco-2 Cell Permeability of Structurally Diverse Small Molecular Weight Compounds Pharm. Res. 1998, 15, 1490-1494
31. Volpe, D. A.; Faustino, P. J.; Ciavarella, A. B.; Asafu-Adjaye, E. B.; Ellison, C. D.; Yu, L. X.; Hussain, A. S. Classification of Drug Permeability with a Caco-2 Cell Monolayer Assay Clin. Res. Regul. Affairs 2007, 24, 39-47
32. Incecayir, T.; Tsume, Y.; Amidon, G. L. Comparison of the Permeability of Metoprolol and Labetalol in Rat, Mouse, and Caco-2 Cells: Use as a Reference Standard for BCS Classification Mol. Pharmaceutics 2013, 10, 958-966
33. Weiss, P.; Hersey, R. M.; Dujovne, C. A.; Bianchine, J. R. The Metabolism of Amiloride Hydrochloride in Man Clin. Pharmacol. Ther. 1969, 10, 401-406
34. Bergan, T.; Midtvedt, T.; Erikssen, J. Human Pharmacokinetics of Cephalexin Pharmacology 1970, 4, 264-472
35. Wright, S. H.; Wunz, T. M. Amiloride Transport in Rabbit Renal Brush-Border Membrane Vesicles Am. J. Physiol. 1989, 256, F462-F468
36. Dantzig, A. H.; Bergin, L. Uptake of the Cephalosporin, Cephalexin, by a Dipeptide Transport Carrier in the Human Intestinal Cell Line, Caco-2 Biochim. Biophys. Acta 1990, 1027, 211-217
37. Camenisch, G.; Alsenz, J.; van de Waterbeemd, H.; Folkers, G. Estimation of Permeability by Passive Diffusion through Caco-2 Cell Monolayers Using the Drugs' Lipophilicity and Molecular Weight Eur. J. Pharm. Sci. 1998, 6, 317-324
38. Lewis, D. F. Human Cytochromes P450 Associated with the Phase 1 Metabolism of Drugs and Other Xenobiotics: A Compilation of Substrates and Inhibitors of the CYP1, CYP2 and CYP3 Families Curr. Med. Chem. 2003, 10, 1955-1972
39. Lilja, J. J.; Raaska, K.; Neuvonen, P. J. Effects of Grapefruit Juice on the Pharmacokinetics of Acebutolol Br. J. Clin. Pharmacol. 2005, 60, 659-663
40. Cummings, A. J.; King, M. L. Urinary Excretion of Acetylsalicylic Acid in Man Nature 1966, 209, 620-621
41. Matsubayashi, K.; Matsumoto, H.; Fukui, Y. Contribution of Cytochrome P450 3A Pathway to Bromocriptine Metabolism and Effects of Ferrous Iron and Hypoxia-Re-Oxygenation on its Elimination in the Perfused Rat Liver J. Pharm. Pharmacol. 1997, 49, 551-557
42. Jamali, F.; Brocks, D. R. Clinical Pharmacokinetics of Ketoprofen and its Enantiomers Clin. Pharmacokinet. 1990, 19, 197-217
43. McNeil, J. J.; Louis, W. J. Clinical Pharmacokinetics of Labetalol Clin. Pharmacokinet. 1984, 9, 157-167
44. Kumakura, Y.; Cumming, P. PET Studies of Cerebral Levodopa Metabolism: a Review of Clinical Findings and Modeling Approaches Neuroscientist 2009, 15, 635-650
45. Alpen, E. L.; Mandel, H. G.; Rodwell, V. W.; Smith, P. K. The Metabolism of C14 Carboxyl Salicylic Acid in the Dog and in Man J. Pharmacol. Exp. Ther. 1951, 102, 150-155
46. Veal, G. J.; Back, D. J. Metabolism of Zidovudine Gen. Pharmacol. 1995, 26, 1469-1475